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Introduction
Lung cancer is a leading cause of cancer deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for about 80% of all lung cancers. The disease is rarely curable, with an overall 5-year survival rate of only 15%. With current platinum-based chemotherapy regimens, median survival is 7-10 months for advanced disease (Schiller et al., 2002) .
Recently it has become apparent that NSCLC is a heterogeneous disease, with many cellular and molecular changes potentially contributing to its development. Accordingly, emphasis has been shifting to targeting subsets of lung cancers based on specific cellular properties (Carbone, 2009 ).
Nitric oxide (NO) is a signaling molecule, a toxicant, and an anti-oxidant under various conditions, with a broad spectrum of actions in physiological and pathological processes. Both pro-and anti-cancer activities have been described, depending on cell type and conditions, the source of NO, its concentration, rate of release, and other factors (Kröncke et al., 1997; Hofseth et al., 2003; Pacher et al., 2007) . NO donor drugs have induced apoptosis in several types of human cancer cells (Bonavida et al., 2006; Bonavida et al., 2008; Huerta et al., 2008) , including prostate (Royle et al., 2004) and colon (Jarry et al., 2004) ; in general the concentrations required have suggested limited clinical applicability. In contrast, the diazeniumdiolate-based NO-donor prodrug, O 2 -(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-K) (Fig. 1) , is highly cytotoxic to leukemia and multiple myeloma cell lines and patientderived multiple myeloma cells, with IC 50 values ranging from 0.2 to 1.2 µM (Shami et al., 2003; Kiziltepe et al., 2007) . Importantly, JS-K was selectively cytotoxic towards cancer cells: at concentrations at which it inhibited the proliferation of multiple myeloma This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on October 20, 2010 as DOI: 10.1124 at ASPET Journals on jpet.aspetjournals.org Downloaded from JPET #174904 5 cells, JS-K had no significant toxicity towards normal peripheral blood mononuclear cells or bone marrow stromal cells (Kiziltepe et al., 2007) .
Other types of cancer cells were also effectively killed by JS-K, including prostate cancer (Shami et al., 2003) and hepatoma cells (Ren et al., 2003) . A survey of the NCI panel of 51 cancer cell lines suggested sensitivity of renal cancers, and correspondingly we found about 10-fold selectivity observed for renal cancer cells, compared with noncancerous renal epithelial cells (Chakrapani et al., 2008) . 
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6 Methods JS-K synthesis and chemicals. JS-K was synthesized as described previously (Saavedra et al., 2001) . All other chemicals were obtained from Sigma (St. Louis, MO).
siRNA to 6 isoforms of PRX (sc-37151) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). HiPerfect transfection reagent and AllStars non-silencing siRNA control were from Qiagen (Valencia, CA).
Cell culture and proliferation assay. Cell lines were obtained from the American Type Culture Collection (Manassas, VA) and cultured according to the supplier's protocol.
For proliferation assays cells were seeded at 2 x 10 4 per well in 96-well plates and allowed to adhere for 24 h. JS-K was prepared as 10 mM stock solution in DMSO.
Increasing drug concentrations in 10 µL of PBS were added to 100 µL of the culture medium for 48 h. MTT assay (Promega, Madison, WI) was performed according to the manufacturer's protocol. Each concentration was represented in six repeats, and the screening was performed as at least two independent experiments. IC 50 values were calculated using Sigma Plot software (Systat Software, Chicago, IL). Comet assay. The alkaline comet assay was performed as described (Romanowska et al., 2007) .
In vivo
Statistical analysis.
All experiments (with the exception of the proliferation assay, which is described above) were performed at least three times, each time at least in triplicate. Results are presented as averages ± SE. Statistical tests were carried out using GraphPad Instat version 3.00 (GraphPad Software, San Diego, CA (Table 1) . Six cell lines were inhibited by JS-K in the range of 0.33 -1.01 µM and were thus as sensitive as leukemia cells (Shami et al., 2003; Shami et al., 2006) or multiple myeloma cells (Kiziltepe et al., 2007) . Sensitive H1703 cells and resistant H1944 cells
were chosen for assessment of activity of JS-K in vivo against xenografted tumor cells in athymic mice. These cell lines have very similar doubling times. JS-K significantly reduced growth of both H1703 and H1944 human NSCLC cells when compared with cells in control animals treated with vehicle only (Fig. 2) . The growth inhibition was much more pronounced for H1703 xenografts than for H1944 cells, as predicted from the cell culture results (Table 1) , although H1944 cells growth in vivo was also significantly inhibited (Fig. 2B) . Importantly, the treatment with either vehicle or JS-K did not affect body weight (see legend to Fig. 2 ). Serum samples collected from the animals at termination were tested for levels of cytokines; there were no significant differences in levels of IL-1β, IL-2, IL-4, IL-5, IL-10, IL-12t, IFNγ or TNFα between the JS-K-treated and control groups.
JS-K effectiveness in inhibiting lung cancer cells' growth correlated with
intracellular ROS/RNS level. We sought to determine the reasons behind the differences in sensitivity to JS-K between the cell lines. Information is available regarding the origin and cancer genes mutational status of some of the cell lines used (Phelps et al., 1996; Romanowska et al., 2007) (Table 1 ). There was no obvious association between JS-K toxicity and mutational status of p53 or K-ras. The cell lines had previously been characterized by us with regard to levels of reactive oxygen species (ROS) (Romanowska et al., 2007) . Inspection of the assembled data suggested that JS-K was most effective against cell lines characterized by high levels of ROS, as detected by the oxidation-sensitive fluorophore, 5-(and 6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate (DCF). It should be noted that this fluorophore is also oxidized by reactive nitrogen species (RNS) such as peroxynitrite. (Halliwell and Whiteman, 2004) There was a strong and statistically significant correlation between endogenous ROS/RNS (DCF fluorescence) and JS-K toxicity, measured as IC 50 values (P = 0.0004, r = -0.75; Fig. 3A ). IC 50 values did not correlate significantly with total levels of superoxide as measured by nitroblue tetrazolium (NBT) reduction (Romanowska et al., 2007) (Supplementary Fig. S1 ).
This article has not been copyedited and formatted. The final version may differ from this version. To confirm a controlling role for ROS/RNS in lung cancer cells' susceptibility to JS-K, we demonstrated that the anti-oxidant N-acetylcysteine (NAC) abrogated the effect of JS-K in the drug-sensitive H1703 cell line (Fig. 3B ). Buthionine sulfoximine (BSO), a prooxidant via glutathione (GSH) depletion, increased effectiveness of JS-K in a dosedependent way in H1703 cells (Fig. 3B) . BSO also potentiated the JS-K effect in the less sensitive H1944 cells (Fig. 3C ).
Several anti-oxidant enzymes may contribute to regulation of steady-state levels of ROS in cells. In our panel of NSCLC cells, ROS/RNS did not correlate with levels of MnSOD, CuZnSOD, catalase, glutathione peroxidase (GPX1) or peroxiredoxins (PRX) 2 and 5 (not shown). However, there was a significant negative correlation of ROS/RNS with PRX 1, 3, 4 and 6 ( Fig. 4A and Supplementary Fig. S2 ), supporting the importance of these enzymes in the anti-oxidant defense system of lung cancer cells.
In addition to their action on peroxides, PRXs are also recognized as highly efficient peroxynitrite scavengers (Ferrer-Sueta and Radi, 2009 ). Protein levels of PRX1 had a strong negative correlation with ROS/RNS and a strong positive correlation with the IC 50 values for JS-K (Fig. 4A ). There was a similar though less pronounced correlation with PRX6 ( Supplementary Fig. S2 and S3 ). Down-regulation of the PRXs with a pool of siRNAs resulted in a significant increase in cell killing by 0.5 µM JS-K (Fig. 4B ). There with the NO-specific reagent 4-amino-5-methylamino-2',7'-difluorofluorescein-diacetate (DAF-FM), and occurred in both the sensitive H1703 and the resistant H1944 cell lines (Fig. 5A) . There was also an increase in DCF-reactive material over this time frame in H1703 cells, but not H1944 cells (Fig. 5B) , suggesting that pre-existing high levels of ROS/RNS were required for generation of additional ROS/RNS. (Fig. 6B) . Involvement of superoxide was also shown using a superoxide scavenger Tiron, which had a protective effect against JS-K toxicity in the H1703 cell line (Fig. 6C ).
Effects of JS-
These effects in the mitochondria suggested the likelihood of an overall change in the redox balance in the H1703 cells, and this was confirmed by a decrease in reduced glutathione (GSH) level and increase in its oxidized (GSSG) form (Table 2) . In addition to indirect effects mediated via mitochondrial actions, JS-K may have a direct depleting effect on GSH. JS-K is activated to release NO by nucleophilic aromatic substitution of GSH at the aryl group, leading to Meisenheimer complex formation, and this reaction can be accelerated by glutathione S-transferases ( Fig. 1) (Shami et al., 2003) . Thus JS-K treatment should lead to GSH depletion both by this S N Ar reaction and through GSH oxidation by the observed increase in ROS/RNS (Fig. 5B) . JS-K treatment reduced levels of GSH and increased levels of glutathione disulfide (GSSG) in the resistant cell line H1944 as well (Table 2) . Untreated H1703 cells have more GSH than H1944 cells. This could favor JS-K toxicity in two ways: JS-K may be more effectively cleaved in the cells containing higher levels of GSH, and kinetic studies indicated that high GSH may in fact favor apoptosis due to its reaction with antiapoptotic species (Bagci et al., 2008) .
Toxicity of JS-K in sensitive cells is associated with induction of the intrinsic apoptotic pathway.
GSH depletion leading to redox imbalance, as demonstrated above, may activate the intrinsic apoptotic pathway initiator Bax by its oxidation-dependent dimerization and mitochondrial fraction within 20 min after treatment with 1 µM JS-K (Fig. 7B) . Loss of mitochondrial membrane potential was detected after 1-h incubation with 1 µM JS-K;
there was marked loss of this membrane potential with 10 µM JS-K (Fig. 7A ).
Cytochrome c release into the cytosol was detected 1 h after JS-K treatment was initiated (Fig. 7C) . Apoptosis was activated early, as evidenced by cleaved caspases 3 and 7 (1 h), and cleaved PARP (1 h) (Fig. 7D ). These effectors of apoptosis were not seen in the resistant H1944 cells, even at a 10-fold higher dose of JS-K (Fig. 7D) . In H1944 cells 8-h treatment with 10 μM JS-K did not activate apoptosis ( Fig. 7D ) and 24-h treatment led only to a weak apoptotic response, as indicated by PARP and caspase 7 cleavage (Fig. 7E) . However, pretreatment of H1944 cells with 1 mM BSO for 16 h followed by JS-K treatment for 24 h resulted in a strong apoptotic signal (Fig. 7E) , confirming the likely involvement of pre-existing oxidative stress in initiating of apoptosis.
DNA damage contributed to JS-K's toxicity. Previously we noted, in the NSCLC cell line panel, a correlation between DNA strand break damage as assessed by the comet assay, and levels of superoxide; baseline levels of total superoxide were low in H1703 cells compared to other lines, as indicated by the NBT assay (Romanowska et al., 2007) . Correspondingly, the increase in mitochondrial superoxide in H1703 cells after JS-K treatment (Fig. 6A ) was associated with extensive DNA damage within 1 h, with no effect seen in the resistant H1944 cell line (Fig. 8A) . By 24 h massive damage was apparent in H1703 cells (Fig. 8A, B ). 1-(2,4-Dinitrophenyl)-4-carboethoxypiperazine , an analogue of JS-K that does not release NO, did not cause DNA strand break damage (Fig. 8C) . express only low levels of mutant inactive p53 (Phelps et al., 1996) , and as expected no alterations in p53 levels or phosphorylation were observed after JS-K treatment; p73 was expressed at low levels but also was not altered (not shown).
Discussion
Lung cancer is rarely curable, despite the advances in understanding molecular mechanisms of cancer and new anti-cancer drug development. Novel therapeutic strategies are critically needed. In this report we demonstrate that the diazeniumdiolate-based nitric oxide-releasing prodrug JS-K is highly effective against a third of the non-small cell lung cancer cell lines studied here and is also active in vivo. by inhibition of cytochrome c oxidase (Brookes et al., 1999; Shiva et al., 2001; Bonavida -et al., 2006; Brown and Borutaite, 2006) . A low concentration (1 μM) of an NOreleasing chemical caused a marked increase in DCF signal in both cells and isolated mitochondria (Borutaite and Brown, 2003) . Inhibition of catalase at low NO levels is also possible (Brown and Borutaite, 2006; Rauen et al., 2007) . Engagement of the intrinsic mitochondrial pathway is typical for NO-induced apoptosis (Li and Wogan, 2005; Pacher et al., 2007) . Direct toxic effects on mitochondrial membranes may have contributed to cytochrome c release and apoptosis.
DNA damage was also extensive and contributed to JS-K's toxic potential, as indicated by the apparent protective effect of high OGG1 levels. The demonstrated increase in superoxide and probable increase in peroxynitrite likely caused this damage;
previously we noted a correlation between basal superoxide levels and DNA damage in our panel of lung adenocarcinoma cell lines (Pacher et al., 2007; Romanowska et al., 2007) . Oxidative DNA damage is predominantly repaired by base excision repair (BER), and 8-oxoguanine glycosylase (OGG1) is responsible for most BER activity in humans. Both NO and peroxynitrite are capable of inhibiting OGG1 activity (Jaiswal et al., 2001) , and may lead to further increase in DNA damage. Effects of DNA damage were p53-independent in H1703 cells; the mechanisms will need to be elucidated in further studies. Induction of apoptosis by NO or peroxynitrite donors has been described in other types of p53-deficient cells (Taylor et al., 2007) .
Until now the therapeutic effectiveness of NO-generators against lung cancers has not seemed likely (Kashfi et al., 2002; Bentz et al., 2004; Chanvorachote et al., 2006; Bentz et al., 2007) . Results presented here show that, on the contrary, JS-K is empirically quite effective against a substantial percentage of lung cancer cell lines that are apparently vulnerable because of a combination of high ROS/RNS, low anti-oxidant PRX1, and low OGG1 DNA repair enzyme. PRX1 and OGG1 proteins could be easily quantified in tumor surgical or biopsy samples, for selection of candidate lung cancer patients for JS-K therapy. 
